ORIGINAL RESEARCH
Published on 09 Jun 2025
An integrated approach based on FDA adverse event reporting system, network pharmacology, molecular docking, and molecular dynamics simulation analysis to study the cardiac adverse reactions and mechanism of action of osimertinib
doi 10.3389/fphar.2025.1619517
- 260 views